Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
ONE-YEAR FOLLOW-UP OF CONTINUOUS ASPIRATION MECHANICAL THROMBECTOMY FOR THE MANAGEMENT OF INTERMEDIATE-HIGH AND HIGH-RISK PULMONARY EMBOLISM: WHAT IS THE LINE BETWEEN UTILITY AND FUTILITY?
Session:
CO 17 - Interventional Cardiology-TEP
Speaker:
Ana Rita Pereira
Congress:
CPC 2021
Topic:
H. Interventional Cardiology and Cardiovascular Surgery
Theme:
25. Interventional Cardiology
Subtheme:
25.3 Non-coronary Cardiac Intervention
Session Type:
Comunicações Orais
FP Number:
---
Authors:
Ana Rita F. Pereira; Rita Calé; Filipa Ferreira; Mariana Martinho; Sofia Alegria; Gonçalo Jácome Morgado; Cristina Dantas Martins; Melanie Ferreira; Ana Gomes; Tiago Judas; Filipe Gonzalez; Corinna Lohmann; Débora Repolho; Pedro Santos; Ernesto Pereira; Maria José Loureiro; Hélder Pereira
Abstract
<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Cambria"><strong><span style="font-family:Calibri">Introduction:</span></strong><span style="font-family:Calibri"> Percutaneous catheter-directed treatments have emerged at the last decade for the management of acute high- or intermediate-high-risk pulmonary embolism (PE). Good short-term efficacy and safety have been published, but there are limited data regarding medium- to long-term outcomes. We aimed t</span></span></span><span style="font-size:12pt"><span style="font-family:Cambria"><span style="font-family:Calibri">o evaluate 1-year all-cause mortality of acute high- and intermediate-high-risk PE patients (pts) treated with continuous aspiration mechanical thrombectomy.</span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Cambria"><strong><span style="font-family:Calibri">Methods:</span></strong><span style="font-family:Calibri"> Twenty-nine consecutive pts with acute central PE (mean age 67.2±14.4 years; 72.4% female; 24.1% active cancer; Charlson comorbidity index 4.5±2.1; 82.8% in class>III of original PESI score; 44.8% high-risk PE) were treated with the Indigo Mechanical Thrombectomy System (Penumbra, Inc) between 03/2018 and 03/2020. Clinical success was defined as improvement in hemodynamic and/or oxygenation parameters or pulmonary hypertension or right heart strain at 48 hours after intervention plus survival to hospital discharge. Data regarding severe adverse events potentially related to the procedure, in-hospital and 1-year all-cause mortality were collected.</span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Cambria"><strong><span style="font-family:Calibri">Results:</span></strong><span style="font-family:Calibri"> Clinical success was 75.9% with a significant improvement in mean paO2/fiO2 ratio (+77.1±103.2; p<0.01), shock index (-0.4±0.4, p<0.01), need for aminergic support (-75.0%, p<0.01), right ventricular function (66.6%, p<0.01) and systolic pulmonary arterial pressure (-10.2±11.5mmHg, p<0.01) at 48 hours after procedure. In-hospital survival rate was 82.8% but severe adverse events potentially related to the procedure occurred in 3 pts (10.3%). One-year follow-up was completed in 93.1% of cases and all-cause mortality rate was 34.5% (n=10 of which half occurred during the index hospital stay). Higher scores of Charlson comorbidity index (5.8±1.9 vs 3.7±1.9, p=0.01) and <em>de novo</em> atrial fibrillation at admission (40% vs 0%, p<0.01) were associated with higher 1-year all-cause mortality occurrence and were identified as 2 independent risk predictors by multivariate Cox regression. Kaplan-Meier curves confirmed its significant influence in 1-year survival free of adverse event (Figure). Time among diagnosis and percutaneous treatment (p=0.99), PESI score (p=0.24) and other clinical, haemodynamic and echocardiographic features did not influence mortality and suggest similarity of the PE severity at baseline. Technical characteristics were also not associated with mortality.</span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Cambria"><strong><span style="font-family:Calibri">Conclusions:</span></strong><span style="font-family:Calibri"> Aspiration thrombectomy for acute high- and intermediate-high-risk PE was feasible with a high clinical success rate. One-year all-cause mortality was elevated and predicted by high comorbidity index and <em>de novo</em> atrial fibrillation at admission. This data support the national expansion of this new PE treatment, but probably and as similar to other invasive techniques, we need to take into account comorbidities and avoid futility in multimorbidity pts.</span></span></span></p>
Our mission: To reduce the burden of cardiovascular disease
Visit our site